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Next-generation sequencing (NGS) has enabled efficient high-resolution typing of human
leukocyte antigen (HLA) genes with minimal ambiguity. Most commercially available assays
amplify individual or subgroup of HLA genes by long-range PCR followed by library prepara-
tion and sequencing. The AllType assay simplifies the workflow by amplifying 11 transplant-
relevant HLA genes in one PCR reaction. Here, we report the performance of this unique
workflow evaluated using 218 genetically diverse samples.
Methods
Five whole genes (HLA-A/B/C/DQA1/DPA1) and six near-whole genes (HLA-DRB1/
DRB345/DQB1/DPB1; excluding exon 1 and part of intron 1) were amplified in a multiplexed,
long-range PCR. Manual library preparation was performed per manufacturer’s protocol, fol-
lowed by template preparation and chip loading on the Ion Chef, and sequencing on the Ion
S5 sequencer. Pre-specified rules for quality control and repeat testing were followed; tech-
nologists were blinded to the reference results. The concordance between AllType and refer-
ence results was determined at 2-field resolution. We also describe the ranges of input DNA
and library concentrations, read number per sample and per locus, and key health metrics in
relation to typing results.
Results
The concordance rates were 98.6%, 99.8% and 99.9% at the sample (n = 218), genotype (n
= 1688), and allele (n = 3376) levels, respectively. Three genotypes were discordant, all of
which shared the same G group typing results with the reference. Most ambiguous geno-
types (116 out of 144, 80.6%) were due to the lack of exon 1 and intron 1 coverage for HLA-
DRB1/DRB345/DQB1/DPB1 genes. A broad range of input DNA concentrations and library
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concentrations were tolerated. Per sample read numbers were adequate for accurate geno-
typing. Per locus read numbers showed some inter-lot variations, and a trend toward
improved inter-locus balance was observed with later lots of reagents.
Conclusion
The AllType assay on the Ion Chef/Ion S5 platform offers a robust and efficient workflow for
clinical HLA typing at the 2-field resolution. The multiplex PCR strategy simplifies the labora-
tory procedure without compromising the typing accuracy.
Introduction
Next-generation sequencing (NGS) has been rapidly adopted for HLA typing in clinical labo-
ratories to evaluate donor-recipient histocompatibility. The key advantage of NGS over Sanger
sequencing for high-resolution HLA typing is that NGS can phase the large number of
sequence variants within HLA genes into haplotypes with minimal cis-trans ambiguity [1–3].
In addition, most current NGS HLA typing assays cover full or near-whole target HLA genes,
allowing the detection of clinically relevant variants outside of key exons (exons 2 and 3 of
class I genes and exon 2 of class II genes). The high throughput of NGS enables multiplexed
sequencing of DNA enriched from multiple genes and many samples in one run, which maxi-
mizes the efficiency and lowers the per sample cost.
While sequencing of the whole genome [4], whole exome [5, 6], transcriptome [7, 8], or
captured HLA genes can lead to successful HLA typing, most commercially available NGS
assays amplify target HLA genes by polymerase chain reaction (PCR) followed by library
preparation and sequencing [9–12]. One common approach is the “long-amplicon, short-
read” approach. The whole, or near-whole HLA genes are enriched by PCR, and the amplicons
are fragmented through enzyme digestion and then ligated to barcodes and sequencing adapt-
ers. Short sequencing reads from Illumina and Ion-torrent sequencers are demultiplexed and
mapped to reference sequences to generate HLA typing of 2-field, and up to 4-field, resolution.
This approach has been shown to achieve highly accurate typing results at a shortened turn-
around time [9–12].
For clinical HLA laboratories, workflow efficiency is an important consideration when
selecting an NGS-based HLA typing method. We evaluated the performance of the AllType
assay (One Lambda, West Hills, CA), which enriches 11 HLA genes (HLA- A/B/C/DRB1/
DRB345/DQB1/DQA1/DPB1/DPA1) in one multiplexed PCR reaction followed by library
preparation and sequencing on the Ion Chef/Ion S5 platform. All other amplicon-based com-
mercial assays reported in the literature, to our knowledge, amplify individual or subgroups of
HLA genes by multiple PCR reactions. It is critical to assess the impact of factors, such as tem-
plate DNA and library concentrations, inter-locus balance, and allele balance, on the success
of this assay. Here, we present the results of our evaluation of the AllType workflow using 218
genetically diverse samples.
Materials and methods
Samples and reference typing results
We sequenced 218 unique samples in this study, including 71 de-identified patient samples
(67 EDTA- or citrate-anticoagulated peripheral blood, 2 buccal specimens, and 2 bone marrow
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biopsy specimens), 96 external proficiency test (PT) specimens from three different vendors,
and 51 cell line-derived DNA samples from the Sequence Polymorphism (SP) panel of the 13th
International Histocompatibility Working Group (IHWG). The study falls outside the purview
of the Human Research Protection Office in our institution, because de-identified specimens
were tested, no links will enable the re-identification of subjects, and providers of the speci-
mens were not involved in the design or conduct of the research. High-resolution reference
typing results (2-field) were available for HLA-A/B/C/DRB1/DQB1 in all samples, For
HLA-DPA1/DPB1/DQA1/DRB345, reference typing results were available in 133, 154, 163,
and 153 samples, respectively. Reference typing results for local patient samples were gener-
ated by Sanger sequencing supplemented by sequence-specific oligonucleotide (SSO) and
sequence-specific primer (SSP) methods. Reference results of PT specimens were consensus
results among participating laboratories. Reference results of the SP panel were generated by
the 13th IHWG and 17th International HLA and Immunogenetics Workshop. A total of 341
unique HLA alleles were included in this study, representing 204 common or well-docu-
mented (CWD) P groups (65.4% of all CWD P groups, version 2.0.0) (Table 1, S1 and S2
Tables) [13]. Homozygous genotypes comprised 15–19% of the genotypes at HLA-A/B/C/
DRB1/DQB1 loci. Six null alleles from the current CWD catalog were included in the study,
including A�24:11N, C�04:09N, DRB4�01:03:01:02N, DRB4�02:01N, DRB5�01:08N, and
DRB5�01:10N. Four non-CWD null alleles, B�39:25N, B�15:26N, A�31:14N, and C�07:55N,
were also represented in the study.
Study design
We followed a pre-specified protocol shown in Fig 1 to ensure objective grading of the results.
Samples must meet two health metrics to be graded for concordance: the allele balance must
be 0.2 or higher, and the key exon coverage must be 100%. For failed samples, reanalysis was
performed with an increased number of reads, if available, or the samples were typed for a sec-
ond time. The primary endpoint of the study was the concordance between the AllType results
and the reference results at the 2-field resolution. Technologists were blinded to the reference
results during testing and data analysis. When ambiguity was encountered, we considered the
National Marrow Donor Program (NMDP) policy to prioritize genotypes consisting of com-
mon or well-documented alleles (CWD). Discordant results were investigated to identify the
potential cause. In addition, we determined the lower limit of genomic DNA concentration for
the assay, the range of read coverage per sample and per locus, the range of key health metrics,
and the ambiguity rate. Finally, we assessed the intra-run and inter-run reproducibility by test-
ing three samples in triplicate and in four independent runs; these runs were performed by
Table 1. Number of unique alleles, CWD P groups, non-CWD alleles in this study.
Locus Count of unique alleles CWD P groups Total CWD P groups Percent of all CWD P groups Alleles outside of CWD P groups
A 62 33 57 57.9% 24
B 91 59 102 57.8% 30
C 40 24 38 63.2% 9
DPA1 6 3 3 100.0% 2
DPB1 31 12 14 85.7% 12
DQA1 16 7 7 100.0% 1
DQB1 18 14 17 82.4% 1
DRB1 60 40 62 64.5% 14
DRB345 17 12 12 100% 4
Total 341 204 312 65.4% 97
https://doi.org/10.1371/journal.pone.0232050.t001
PLOS ONE Evaluation of high-resolution HLA typing by AllType
PLOS ONE | https://doi.org/10.1371/journal.pone.0232050 April 23, 2020 3 / 15
two technologists using three different lot of reagents. Different barcodes were used to index
these reproducibility samples. We evaluated the concordance of the typing results and the cor-
relation of key health metrics. Discordant samples were typed by TruSight HLA v2 and Allo-
Seq Assign (CareDx, Brisbane, CA) on the Illumina platform. The MinION device from
Oxford Nanopore Technologies (ONT) was used to generate long reads to resolve cis-trans
ambiguities in two discordant DPB1 genotypes.
DNA extraction & quantification
Genomic DNA was extracted from blood specimens using the EZ1 DNA Blood 350 μL Kit
(Qiagen, Hilden, Germany) on the EZ1 Advanced XL instrument. The proficiency testing cell
lines (EBV-transformed B cells) from the University of California Los Angeles (UCLA) Immu-
nogenetics Center, local buccal samples, and local biopsy specimens were extracted manually
using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).
AllType workflow & HLA typing assignment
The AllType assay (One Lambda, West Hills, CA) amplifies and sequences five whole genes
(HLA- A/B/C/DQA1/DPA1) and six near-whole genes (HLA-DRB1/DRB345/DQB1/DPB1;
exon 1 and part of intron 1 not included) for HLA typing. Target amplification, library prepa-
ration, template preparation and chip loading on the Ion Chef, and sequencing on the Ion S5
Fig 1. Study design.
https://doi.org/10.1371/journal.pone.0232050.g001
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instrument were performed following procedures specified by the vendor. Torrent Suite (Ver-
sion 5.10.1) was used for basecalling, demultiplexing, and managing run-level and barcode-
level data. TypeStream Visual (TSV, Version 1.2; Catalog ALL-11LX_001, ALL-11LX_007 and
ALL-11LX_013; IMGT Version 3.33.0.0) was used to analyze locus-level data to determine
HLA genotypes at 2-field resolution if associated health metrics were met. The default analysis
parameters and health metrics thresholds recommended by the vendor were used throughout
the study except that the allele balance at any locus must be 0.2 or greater, instead of the default
cutoff value of 0.3.
Data analysis
Concordance rates were reported at the sample, genotype, and allele levels. Homozygous
genotypes were treated as two identical alleles at the same locus. DRB345 was treated as one
genotype with up to two detectable alleles at one or two of these three loci depending on the
haplotypes present in any one sample. Run-level quality metrics, including ion sphere parti-
cle (ISP) density, total reads, mean, median or mode read length, test fragment 50AQ17
and 100AQ17, were summarized for all ten runs in this study to define the ranges of these
parameters. At the locus level, we examined the distributions of health metrics (key exon
coverage, allele balance, uniformity, and mismatches in exons) and their impact on typing
results.
Results
Concentrations of genomic DNA (gDNA), PCR amplicons, and individual
libraries
The gDNA concentrations ranged from 5.6 to 80 ng/μL among all samples, and they were not
significantly different between samples with adequate key-exon coverage (n = 207, median
concentration: 25 ng/μL, range: 5.6–80 ng/μL) and those with inadequate coverage for one or
more loci (n = 11, median: 25 ng/μL, range: 18–32 ng/μL) (Mann Whitney test [14], P = 0.58;
Fig 2a).
The amplicon concentrations ranged from 2.0 to 43.8 ng/μL among all samples, and they
were higher in samples with adequate key-exon coverage (median: 21.2 ng/μL, range: 2–43.8
Fig 2. DNA concentrations throughout the AllType workflow. a) Genomic DNA (gDNA). b) PCR amplicons. c)
Individual libraries (at 1:5 dilution). Concentrations for samples with adequate coverage for all loci (n = 207) or
insufficient coverage for at least one loci (n = 11) are plotted separately. Black lines are medians and interquartile
ranges.
https://doi.org/10.1371/journal.pone.0232050.g002
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ng/μL) compared with those with inadequate coverage (median: 13.7 ng/μL, range: 2.2–35.2
ng/μL) (P = 0.04; Fig 2b). However, lower amplicon concentrations could not reliably predict
inadequate key-exon coverage. A receiver operating characteristic (ROC) analysis [15] showed
an area under the curve of 0.682 (P = 0.042). Using< 5 ng/μL as the cutoff value, the sensitivity
and specificity were 45.5% and 96.6%, respectively, for predicting inadequate key-exon
coverage.
The library concentrations (at 1:5 dilution) ranged from 0.0076 to 5.76 ng/μL among all
samples. Although lower library concentrations were enriched in the group with inadequate
coverage, the library concentrations were not significantly different between samples with
adequate key-exon coverage and those with inadequate coverage (P = 0.13; Fig 2c).
We also performed a sensitivity analysis on the effect of input gDNA concentrations. Seven
gDNA specimens from a serial 1:2 dilution of one sample were sequenced in one run. The con-
centrations ranged from 1.5 to 100 ng/μL, which was broader than the concentrations of the
218 regular samples. The PCR amplicon concentrations ranged from 1.8 to 22.4 ng/μL and
correlated well with the input gDNA concentrations (Spearman R = 0.976, P<0.001; Fig 3a).
The library concentrations (at 1:5 dilution) ranged from 0.48 to 1.61 ng/μL and correlated well
with the amplicon concentrations (R = 0.762, P<0.05; Fig 3b). Concordant typing results were
obtained at all input gDNA concentrations, and the negative control (water) was negative.
Sequencing runs and run-level metrics
Two technologists performed ten sequencing runs with 16–48 samples per run. The run-level
quality metrics are summarized in Fig 4. We observed a narrow distribution of 50AQ17
(median: 85%, interquartile range or IQR: 82.7–86.3%) and 100AQ17 (82%, 79.8–83%),
defined as the percentages of the test fragment (TF) sequencing reads with an error rate of 1 in
Fig 3. Concentrations of genomic DNA (gDNA), amplicons, and libraries in the titration study. a) Correlation
between the gDNA concentrations and amplicon concentrations. b) Correlation between the amplicon concentrations
and library concentrations.
https://doi.org/10.1371/journal.pone.0232050.g003
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50 and a minimum length of 50 and 100 bases, respectively. The median percent usable reads
was 50.5% (IQR: 47–52.5%), which was dependent on the percent chip loading (88%, 86.5–
89%), percent enrichment (99%, 99–99.3%), percent clonal ion-sphere particles (62%, 60.5–
63.3%), and final library (82.5%, 77–83.3%) (Fig 4a and 4b). The median read length observed
in this study was 261 bases, and the coefficients of variations (CVs) for the mean, median, and
mode of read lengths across all runs were 13.6%, 15%, and 21.6%, respectively (Fig 4c). The
shorter median read lengths in three runs (approximately 200 bases) were not associated with
any operator (Fig 4d). Importantly, there was no correlation between shorter read lengths and
increased typing errors or ambiguity.
Number of reads per sample and per locus
The number of reads per sample, after demultiplexing, showed a normal distribution in three
representative runs (Fig 5a–5c), all including 32 samples per run but each using a different lot
of AllType PCR primers. The mean reads number per sample ranged from 461,301 to 538,531
among these runs. The TSV software, by default, analyze up to 300,000 reads per sample for
HLA typing. All but one sample in these three runs surpassed this threshold. The outlier in
Run09 had 40,000 reads and was successfully typed with all health metrics met.
We observed the following inter-locus and inter-lot difference in the number of reads
mapped to each HLA locus (Fig 5d–5f). First, the number of reads per locus was higher for cer-
tain class II loci, i.e., DPB1, DQB1, DRB1, and DRB345, than class I loci in all three representa-
tive runs. This difference corresponds to the longer amplicons for these class II loci than those
for class I loci. Second, the read number per locus was unbalanced among class I loci (A, B,
and C) with the Lot 001 reagent (Fig 5d), while the inter-locus balance was improved with the
Lot 007 and 013 reagents (Fig 5e and 5f). The imbalance among DPB1, DQB1, DRB1, and
DRB345 was relatively modest. Third, we also normalized the number of reads per locus as a
percentage of the total reads per sample and compared the values across different representa-
tive runs (Fig 6). Significant inter-lot differences were detected for A, B, C, DPA1, DQA1, and
DQB1, which likely reflect reagent updates by the manufacturer to achieve more balanced cov-
erage for these loci.
Fig 4. Distribution of run-level metrics from ten sequencing runs. a) Metrics for sequencing accuracy of test
fragments (%50AQ17 and %100AQ17) and the percentage of reads usable for analysis. The latter is dependent on the
percentages of ion-sphere particle (ISP) loading, template-positive ISP (enrichment), clonal ISP, and final library. b)
Total reads usable for analysis. c) The mean, median, and mode of read lengths from 10 runs. d) The median read
lengths stratified by technologists. Lines are medians and interquartile ranges.
https://doi.org/10.1371/journal.pone.0232050.g004
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Health metrics: Key-exon coverage, allele balance, and repeat testing
The minimum key-exon coverage was above 100 reads for most samples across all loci (Fig 7a
and 7b), suggesting that excellent coverage can be achieved with 16–48 samples per run. For
Fig 5. Distribution of the number of reads per sample and per locus. The histogram of read count per sample was
plotted for three independent runs performed with three different lots of AllType reagents: a) Run01, Lot001. b)
Run08, Lot007. c) Run09, Lot013. The number of reads per locus was also summarized for these runs: d) Run01,
Lot001. e) Run08, Lot007. f) Run09, Lot013. Each run included 32 barcoded samples. Median (solid line) and
interquartile (dotted line) are shown in the violin plots (d-f).
https://doi.org/10.1371/journal.pone.0232050.g005
Fig 6. Inter-lot comparison of the percentages of total reads mapped to each locus. Each lot is represented by one
run with 32 barcoded samples. Boxes represent the median and interquartile range (IQR); whiskers represent 1.5 IQR.
�� P<0.01, ���� P<0.0001, by ordinary one-way ANOVA.
https://doi.org/10.1371/journal.pone.0232050.g006
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DPA1, DQB1, DRB1, and DRB345, the allele balance deviated from a normal distribution with
a large number of samples affected by significant allele imbalance (Fig 7c).
Five samples had inadequate key-exon coverage, defined as less than 20 valid reads at any
key-exon position for an allele, which was resolved upon reanalysis with additional reads (up
to 600,000 per locus if available). Ten samples were re-typed due to inadequate coverage and
unsuccessful reanalysis, giving a repeat testing rate of 4.6%. Seven of the ten samples passed all
health metrics upon repeat testing. Three of the ten samples did not satisfy the key exon cover-
age for DQB1 in one sample and for DPB1 in all three samples. All three samples were PT sam-
ples stored at 4˚C for over two years. Despite satisfactory gDNA concentrations (18–23 ng/
μL), partial degradation of the specimens was observed on electrophoresis. Among all target
loci, DRB1 (7 samples) was the most commonly affected by inadequate key-exon coverage.
Only one sample had allele imbalance for DPB1 at the 4-field resolution, which did not affect
reporting at the 2-field resolution, and the sample was not re-typed.
Health metrics: Mismatches in exons
A total of 46 mismatches in exons were observed in this study, where the consensus bases from
the sequencing reads differed from the reference alleles called by TSV (S3 Table). These mis-
matches were in non-key exons only, and most were found at the DRB5 locus (67.4%), fol-
lowed by DPA1 (17.4%), C (8.7%), DQA1 (4.4%), and DQB1 (2.2%). The closest 2-field HLA
alleles were assigned as the final typing for comparison with the reference typing results.
Thirty two of the 46 exon mismatches (69.6%) were likely sequencing artifact (S3 Table).
The G>T variant at exon 6 position 12703 (gDNA alignment position, E6-12703) of
DRB5�01:01:01 was the most common mismatch in exons (n = 21) observed in our study,
followed by the same mismatch with DRB5�01:02 (n = 4) and DRB5�02:02:01 (n = 4). These
mismatches occurred primarily with Lot 001 and 007 reagents, but not Lot 013, and their inter-
pretation was confounded by high background at the position suggestive of aberrant read
mapping. Three mismatches occurred in homopolymer regions in three samples, and the
supporting reads for these mismatches were all in one direction rather than bidirectional.
Fourteen of the 46 exon mismatches were supported by the sequencing reads (S3 Table).
Except for two synonymous mutations, 12 mismatches were missense mutations that were
Fig 7. Distributions of minimum coverage depths in key exons and allele balance. a) Minimum coverage depth for
exon 2 of all loci. b) Minimum coverage depth for exon 3 of class I loci. c) Allele balance. Values from 218 samples are
plotted. For samples that underwent repeat testing, the values from the repeat testing (not the initial run) were
included in the plots. Line and dotted lines in the violin plots represent median and interquartile range (IQR),
respectively.
https://doi.org/10.1371/journal.pone.0232050.g007
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predicted to cause substitutions in the protein sequence outside of the antigen recognition
domains.
Concordance with reference typing and investigation of discordant results
The AllType typing results were concordant with all evaluable genotypes in 215 of the 218
samples, with a sample-level concordance rate of 98.6%. The overall concordance rates at the
genotype and allele levels were 99.8% and 99.9%, respectively. Detailed results for each HLA
locus are reported in Table 2. The three discordant genotypes and our investigation are
described in Table 3. The discordant DRB1 genotype involved alleles in the same G group and
could be explained by a single-base variant in exon 4 that was missed by TSV. The G group
genotype, homozygous DRB1�09:01:02G, was in agreement between AllType and the refer-
ence. The two discordant DPB1 genotypes also share the same G group typing,
DPB1�04:01:01G and DPB1�04:02:01G, and the discrepancies were due to cis-trans ambiguity.
Both samples were PT samples from 2016 and 2017, and the reference typing results appeared
to have considered the key exon (exon 2) only.
We typed the discordant samples by TruSight HLA [10] and AlloSeq Assign (CareDx, Bris-
bane, CA) assays on the Illumina platform. The DRB1 typing by both Illumina-based methods
agreed with the reference. Neither Illumina-based method resolved the cis-trans ambiguity of
the two DPB1 genotypes. Nanopore sequencing generated long reads capable of phasing the
distant variants, which supported the genotype of DPB1�04:01 and DPB1�04:02.
Ambiguity
Ambiguity was encountered in 112 samples for 144 genotypes, and three categories were
described as follows. First, 116 ambiguous genotypes (80.6%) involved DPB1, DQB1, DRB1,
and DRB345 genes and were explained by the lack of exon 1 and intron 1 coverage. Second, 26
ambiguous genotypes (18.1%) were due to cis-trans ambiguity across different exons. All alter-
native genotypes included one or two rare alleles, which did not need to be resolved per cur-
rent NMDP policy and could be reported using existing NMDP codes. Third, ambiguous
genotypes due to intronic variant were frequently identical at the 2-field resolution except in
two cases (1.4%), where B�27:05:02:04Q was listed as an alternative allele. B�27:05:02:04Q has
an A at the 3’ end of intron 2, substituting a commonly observed G; the variant is predicted to
disrupt splicing and result in an altered protein sequence. Upon inspection of the reads
Table 2. Concordance at the genotype and allele levels.
Locus Genotype-level evaluation Allele-level evaluation
Evaluable genotypes� Concordance Concordance rate Evaluable alleles� Concordance Concordance rate
A 218 218 100.0% 436 436 100.0%
B 218 218 100.0% 436 436 100.0%
C 218 218 100.0% 436 436 100.0%
DPA1 133 133 100.0% 266 266 100.0%
DPB1 151 149 98.7% 302 298 98.7%
DQA1 163 163 100.0% 326 326 100.0%
DQB1 217 217 100.0% 434 434 100.0%
DRB1 217 216 99.5% 434 433 99.8%
DRB345 153 153 100.0% 306 306 100.0%
All loci 1688 1685 99.8% 3376 3371 99.9%
� Loci with unsatisfactory health metrics were excluded, including DQB1 in one sample, DPB1 in three samples, and DRB1 in one sample.
https://doi.org/10.1371/journal.pone.0232050.t002
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mapped to the region, B�27:05:02:04Q was ruled out in both cases due to the lack of read
support.
Intra-run and inter-run reproducibility
Three samples for reproducibility evaluation were tested in triplicate in four runs, a total of 12
repeats for each sample. All genotypes were concordant among all repeats with the following
two exceptions. One repeat of sample #1 did not meet the minimum reads requirement and
was excluded from analysis. Sample #3 had allele imbalance for DRB1 in four out of 12 repeats,
which was also excluded from analysis.
To assess the reproducibility of key health metrics, we first examined the pairwise correla-
tion of mean exon 2 coverage across all loci between repeats of each sample. The correlation
of 34 pairs of intra-run repeats showed Pearson coefficients ranging from 0.7 to 1. The inter-
run correlations were lower than intra-run correlations with 17 out of 153 Pearson coeffi-
cients below 0.4, an arbitrary threshold for acceptable correlation. Exclusion of DQB1 from
this analysis improved all coefficients to 0.4 or higher. We also examined the pairwise corre-
lation of allele balance across all loci between repeats of each sample. The correlation of
intra-run repeats showed coefficients ranging from 0.4 to 1. The inter-run correlations were,
again, lower than intra-run correlations with 32 out of 153 Pearson coefficients below 0.4.
Exclusion of DRB1 from this analysis improved all coefficients to 0.4 or higher.
Conclusion & discussion
This study established an excellent accuracy and ambiguity profile for the AllType workflow in
2-field HLA typing. We included genetically diverse samples of multiple specimen types that
are routinely tested in a hospital-based HLA laboratory. We also implemented a pre-specified
policy for repeat testing and concordance grading to ensure an objective evaluation. The assay
tolerated a broad range of input DNA concentrations and individual library concentrations
with a low repeat testing rate. The number of reads per sample and locus were adequate for the
application. With the multiplexed PCR design, we observed some inter-lot variations in the
per-locus reads number, as well as a trend towards a more balanced inter-locus coverage with
later lots of reagents. We also observed increased exon mismatches with earlier lots but not a
later lot of reagent (S3 Table), which underscored the need to characterize these mismatches
during data analysis and to monitor their occurrence for quality assurance purposes. With sat-
isfactory key exon coverage and allele balance, 99.8% of the AllType genotypes were
Table 3. Discordant results and further investigation.
Run-
ID
Barcode Locus Reference typing AllType result Investigation




All health metrics were met. The two genotypes by AllType were due to a
sequence variant in exon 1 that was not covered by the assay. The reference
and AllType genotypes indicated a cis-trans ambiguity across exons 2 and 3.
The ambiguity was not resolved by alternative NGS methods on the Illumina
platform. Long reads spanning exons 2 and 3 generated by nanopore
sequencing were consistent with the reference typing.





All health metrics were met. DRB1�09:01:02:01 has one base difference from
DRB1�09:21 in exon 4 (E4-8874). DRB1�09:31 has a reference sequence that
covers exons 1–3 only; it has one base difference from DRB1�09:01:02:01
and DRB1�09:21 in exon 1. DRB1�09:01 was not included in the genotype by
AllType because the supportive reads were considered as high background
rather than true signal. This seemed to be an idiosyncratic event unique to
this sample, which was typed correctly by a newer version of TSV.
https://doi.org/10.1371/journal.pone.0232050.t003
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concordant with the reference results. For the three discordant genotypes, the AllType results
were clinically acceptable in all three cases, where the G group typing results agreed with the
reference.
Our findings confirm the recent report by Cargou and colleagues on the performance of
the AllType workflow [11]. We also present additional information on the accuracy of 2-field
typing for DQA1 and DPA1, which may be beneficial for solid-organ donor typing [16]. More-
over, we describe the distributions of key health metrics, gDNA and library concentrations,
and reads number per sample and per locus. These data are valuable for quality monitoring,
decision-making on repeat typing, and troubleshooting in times of testing failure. The mini-
mum guidelines on the validation of NGS HLA typing by the American Society for Histocom-
patibility and Immunogenetics (ASHI) also emphasizes the evaluation of health metrics
associated with NGS workflows in clinical HLA laboratories. Related to the report by Cargou
and our study, Barone and colleagues reported the satisfactory performance of a similar work-
flow on the Ion-torrent platform, NXType [12], which features two separate PCR reactions for
class I and II HLA genes, respectively. De Santis’s group also reported a highly accurate meth-
ods based on the Ion-torrent sequencer, and four PCR reactions were used to amplify a total of
11 HLA genes [17].
The “long-amplicon, short-reads” approach to NGS-based HLA typing has also been imple-
mented successfully on the Illumina platform. Several commercially available assays have
achieved comparable accuracy and efficiency based on well-designed validation studies [9, 10,
18–20]. The general workflows of these assays are similar to AllType, except for some differ-
ences in the PCR strategy, barcoding method, and sequencing chemistry. Typical for these
assays, target HLA genes are amplified separately and then indexed with barcodes for each
locus or each sample. For example, the Omixon assay analyzes up to 40,000 reads for locus-
indexed libraries and 200,000 reads for sample-indexed libraries [9]. With the Illumina
sequencing chemistry, the sequencing reads have a lower error rate than reads from the Ion-
torrent sequencer; the paired-end reads with longer library fragments may theoretically enable
the phasing of more distant variants. Nevertheless, Ion-torrent S5 has a shorter sequencing
time of approximately 7 hours; the higher error rate and its typical read length of 200–300
bases appear to be inconsequential for the AllType application.
Our study has a few limitations. First, this is a single-center, single-platform evaluation
with a modest sample size. While we provided in-depth information on the AllType assay,
other multi-center, multi-platform comparison studies are invaluable in contrasting the per-
formance of different NGS assays relative to each other [21, 22]. Second, our study did not
evaluate HLA typing beyond the 2-field resolution. Two-field HLA typing remains the gold
standard for recipient-donor matching in allogeneic hematopoietic stem cell transplantation
[23]. Few clinical laboratories are currently reporting 3-field or 4-field HLA typing, although a
potential role for this ultra-high resolution (UHR) typing is emerging in several recent studies
[24, 25]. One potential barrier for the validation of UHR typing is the availability of clinical
samples with known 3- and 4-field typing; some reference cell lines typed recently at UHR [21,
26] may be an acceptable alternative. Third, we handled exon mismatches by in-depth review
of read mapping data and did not attempt to verify them by a different method. No mismatch
occurred in key exons during our study; the closest alleles in the HLA/IMGT database [27]
were assigned and used for concordance grading. We took this pragmatic approach to mimic
the intended routine practice in our laboratory. Our current standard operating procedure
also requires that mismatches in key exons that change the protein sequence must be verified
by an orthogonal method.
The future landscape of NGS-based HLA typing will be defined by continued innovation
and clinical investigation. Additional technologies such as the single molecule real-time
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(SMRT) sequencing on the Pacific Biosciences’ platform has been effectively employed for
HLA typing [26, 28, 29]. The technology enables the “long-amplicon, long-reads” approach,
which allows the long-range amplicons to be sequenced as a whole without fragmentation.
This feature simplifies the library preparation and enhances the capability of phasing distant
variants. Oxford Nanopore Technologies may offer another option for implementing the
“long-amplicon, long-reads” approach for HLA typing [30–32], although better bioinformatics
tools are needed to overcome the high error rate of the nanopore sequencing reads. On the
other end of the spectrum, Lange and colleagues took the “short-amplicon, short-reads”
approach and developed a workflow to sequence selected exons only on the Illumina platform.
With the bypass of conventional library preparation and a high degree of automation, this
method maximized the efficiency for donor registry HLA typing [33, 34]. Together with All-
Type and other Illumina-based assays discussed above, HLA laboratories will have many good
options to meet their diverse clinical needs.
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